SPI-2/CrmA inhibits IFN-β induction by targeting TBK1/IKKε

Yue Qin1, Mi Li2, Sheng-Long Zhou3

  • 1The State Key Laboratory Breeding Base of Basic Science of Stomatology, Hubei Province and Key Laboratory of Oral Biomedicine, Ministry of Education (Hubei-MOST KLOS & KLOBME), School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China. qinyue@whu.edu.cn.

Scientific Reports
|September 7, 2017
PubMed

Insights

Poxvirus proteins serine proteinase inhibitor 2 (SPI-2) and cytokine response modifier A (CrmA) block antiviral defenses. These proteins inhibit interferon-beta (IFN-β) production by disrupting key signaling complexes, revealing a novel poxvirus immune evasion strategy.

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Viruses employ diverse strategies to evade host immune responses.
  • Poxvirus proteins SPI-2 and CrmA are known to interfere with host antiviral mechanisms, including apoptosis and cytokine activation.
  • Interferon-beta (IFN-β) is a critical cytokine in the innate immune response against viral infections.

Purpose of the Study:

  • To investigate the role of poxvirus SPI-2 and CrmA in regulating virus-induced IFN-β production.
  • To elucidate the molecular mechanism by which SPI-2 and CrmA modulate the IFN-β signaling pathway.

Main Methods:

  • Ectopic expression of SPI-2 and CrmA in host cells.
  • RNA interference (RNAi) to knockdown SPI-2 expression.
  • Analysis of IFN-β and downstream gene induction.
  • Co-immunoprecipitation assays to study protein-protein interactions.

Main Results:

  • SPI-2 and CrmA were identified as negative regulators of virus-induced IFN-β production.
  • Ectopic expression of SPI-2 or CrmA inhibited IFN-β and downstream gene expression.
  • Knockdown of SPI-2 enhanced VACV-induced antiviral gene transcription.
  • SPI-2 and CrmA were found to associate with TBK1 and IKKε, disrupting the MITA-TBK1/IKKε-IRF3 signaling complex.

Conclusions:

  • SPI-2 and CrmA represent a novel mechanism for poxvirus immune evasion by inhibiting IFN-β induction.
  • These proteins interfere with the MITA-TBK1/IKKε-IRF3 pathway, a key component of the innate antiviral response.
  • Understanding this mechanism provides insights into poxvirus pathogenesis and potential therapeutic targets.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633